Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RMC-6291
Elironrasib · 3 trials · 10 indications
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs and vital signs
Number of participants with dose limiting toxicities
Incidence and severity of treatment-emergent AEs and serious AEs as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5
Number of patients with clinically significant changes in vital signs
Number of patients with clinically significant changes in clinical laboratory test values
Number of participants with dose limiting toxicities
Number of patients with clinically significant changes in ECGs
Overall response rate per RECIST v1.1 as assessed by blinded independent central review (BICR)
| Arm | Type | Description |
|---|---|---|
| Subprotocol A: KRAS G12C-Mutated Solid Tumors | EXPERIMENTAL | RMC-6291 (BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W) |
| Subprotocol B: RAS-mutated NSCLC | EXPERIMENTAL | RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W) |
| Subprotocol C: RAS G12D-mutated NSCLC | EXPERIMENTAL | RMC-9805 (QD or BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W). |
| Subprotocol D: RAS G12D-mutated NSCLC | EXPERIMENTAL | RMC-9805 (QD) |
| Elironrasib Monotherapy | EXPERIMENTAL | Phase 2 only |
| Daraxonrasib Monotherapy | EXPERIMENTAL | Phase 2 only |
| Daraxonrasib + Elironrasib Combination | EXPERIMENTAL | Phase 1b and 2 |
| RMC-6291 | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Name | Type | Description |
|---|---|---|
| RMC-6291 | DRUG | Oral tablet |
| RMC-6236 | DRUG | Oral tablet |
| Pembrolizumab | DRUG | IV Infusion |
| Cisplatin | DRUG | IV Infusion |
| Carboplatin | DRUG | IV Infusion |
| Pemetrexed | DRUG | IV infusion |
| RMC-9805 | DRUG | Oral Tablet |
| Elironrasib | DRUG | oral tablets |
| Daraxonrasib | DRUG | oral tablets |
Inclusion criteria: All Patients (unless otherwise noted): * ≥ 18 years of age * ECOG PS is 0 to 1 * Adequate organ function as outlined by the study * Received prior standard therapy appropriate for tumor type and stage * Must have pathologically documented, locally advanced or metastatic KRAS G1...
Elironrasib is an investigational small molecule being studied for the treatment of advanced KRAS G12C-mutant solid tumors, with a primary focus on non-small cell lung cancer (NSCLC). It is also being evaluated in colorectal cancer and pancreatic ductal adenocarcinoma. Elironrasib has not been approved by the FDA and remains in clinical development.
Elironrasib targets KRAS G12C, a mutant form of the KRAS protein. KRAS G12C is a driver mutation found in several solid tumors, including non-small cell lung cancer. By binding this target, Elironrasib is designed to inhibit RAS signaling that promotes tumor growth.
Elironrasib is being developed by Revolution Medicines, Inc., which trades on the Nasdaq under the ticker RVMD. The company is running the clinical program for Elironrasib as both a monotherapy and in combination with daraxonrasib in patients with advanced KRAS G12C-mutant solid tumors.
Elironrasib is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The Phase 1 program includes dose escalation and dose expansion studies evaluating Elironrasib as a monotherapy and in combination therapy in patients with advanced KRAS G12C-mutant solid tumors.
Elironrasib is being evaluated in three Phase 1 trials: NCT06162221, a study of RAS(ON) inhibitors in advanced RAS-mutated NSCLC; NCT06128551, a study of Elironrasib and daraxonrasib as monotherapies and combination therapy in advanced KRAS G12C-mutant solid tumors; and NCT05462717, a dose escalation and expansion study of RMC-6291 monotherapy.
Yes, Elironrasib is also known as RMC-6291. RMC-6291 is the earlier code name used for the same investigational KRAS G12C-targeted compound, and it appears under that name in the Phase 1 monotherapy trial NCT05462717. Both names refer to the same drug candidate being developed by Revolution Medicines.